Delphine Horeau-Langlard
Overview
Explore the profile of Delphine Horeau-Langlard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
327
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boucly A, Montani D, Bauer F, Artaud-Macari E, Bergot E, Boissin C, et al.
Eur Respir J
. 2025 Jan;
PMID: 39884763
Background: European guidelines recommend initial monotherapy in PAH patients with cardiovascular (CV) comorbidities based on the limited of evidence for combination therapy in this growing population. Methods: A retrospective analysis...
2.
Jais X, Brenot P, Bouvaist H, Jevnikar M, Canuet M, Chabanne C, et al.
Lancet Respir Med
. 2022 Aug;
10(10):961-971.
PMID: 35926542
Background: Riociguat and balloon pulmonary angioplasty (BPA) are treatment options for inoperable chronic thromboembolic pulmonary hypertension (CTEPH). However, randomised controlled trials comparing these treatments are lacking. We aimed to evaluate...
3.
Delbove A, Senage T, Gazengel P, Tissot A, Lacoste P, Cellerin L, et al.
Ther Adv Respir Dis
. 2022 Jul;
16:17534666221110354.
PMID: 35894432
Background: Anastomotic complications are common after lung transplantation (1.4-33% of cases) and still associated with a high morbi-mortality. Methods: The current study is a monocenter retrospective analysis of symptomatic anastomotic...
4.
Benkalfate N, Eschapasse E, Georges T, Leblanc C, Dirou S, Melscoet L, et al.
BMJ Open Respir Res
. 2022 Mar;
9(1).
PMID: 35264326
Introduction: COVID-19 sequelae are numerous and multisystemic, and how to evaluate those symptomatic patients is a timely issue. Klok proposed the Post-COVID-19 Functional Status (PCFS) Scale as an easy tool...
5.
Boucly A, Weatherald J, Savale L, de Groote P, Cottin V, Prevot G, et al.
Eur Respir J
. 2021 Nov;
59(6).
PMID: 34737227
Introduction: Contemporary risk assessment tools categorise patients with pulmonary arterial hypertension (PAH) as low, intermediate or high risk. A minority of patients achieve low risk status with most remaining intermediate...
6.
Boucly A, Savale L, Jais X, Bauer F, Bergot E, Bertoletti L, et al.
Am J Respir Crit Care Med
. 2021 Jun;
204(7):842-854.
PMID: 34185620
The relationship between the initial treatment strategy and survival in pulmonary arterial hypertension (PAH) remains uncertain. To evaluate the long-term survival of patients with PAH categorized according to the initial...
7.
Lacoste-Palasset T, Chaumais M, Weatherald J, Savale L, Jais X, Price L, et al.
Ann Am Thorac Soc
. 2021 Jan;
18(8):1306-1315.
PMID: 33502958
Pulmonary hypertension (PH) has been described in patients treated with leflunomide. To assess the association between leflunomide and PH. We identified incident cases of PH in patients treated with leflunomide...
8.
Savale L, Guimas M, Ebstein N, Fertin M, Jevnikar M, Renard S, et al.
J Hepatol
. 2020 Sep;
73(5):1293-1294.
PMID: 32907706
No abstract available.
9.
Savale L, Guimas M, Ebstein N, Fertin M, Jevnikar M, Renard S, et al.
J Hepatol
. 2020 Mar;
73(1):130-139.
PMID: 32145258
Background & Aims: Long-term outcomes in portopulmonary hypertension (PoPH) are poorly studied in the current era of pulmonary hypertension management. We analysed the effect of pulmonary arterial hypertension (PAH)-targeted therapies,...
10.
Boucly A, Cottin V, Nunes H, Jais X, Tazi A, Prevot G, et al.
Eur Respir J
. 2017 Oct;
50(4).
PMID: 29051269
Studies reporting the effects of modern strategies with pulmonary arterial hypertension (PAH)-targeted therapies in sarcoidosis-associated pulmonary hypertension (S-APH) are limited.Clinical and haemodynamic data from newly diagnosed patients with severe S-APH...